Press Releases

Circassia’s Allergy Therapy Begins Phase II Clinical Trial in Asthma Patients

Circassia Ltd, a specialty biopharmaceutical company focused on allergy, announced today that it has initiated a phase II clinical study of its ToleroMune® technology in allergy patients with asthma. The trial builds on positive phase...

View details

Circassia Completes Patient Recruitment For Phase II Clinical Trial Of ToleroMune Allergy Treatment

OXFORD, UK – 7 January 2009 – Circassia Ltd, a specialty biopharmaceutical company focused on allergy and critical care, today announced that following successful clinical results achieved in 2008 with its ToleroMune® anti-allergy technology, the...

View details

Circassia Acquires North American and Japanese rights to Dopexamine

Circassia Ltd, a specialty biopharmaceutical company focused on the fields of allergy and critical care, announced today that it has acquired the US, Canadian and Japanese development and commercialization rights to dopexamine from the international...

View details

Circassia Initiates Further Phase II Clinical Study of ToleroMune® Anti-Allergy Technology

Circassia Ltd, a specialty biopharmaceutical company focused on the fields of allergy and critical care, today announced the start of a further phase II clinical study of its ToleroMune® technology in the field of cat...

View details

Circassia Achieves Successful Phase II Clinical Results With ToleroMune® Anti-Allergy Technology

Circassia Ltd, a specialty biopharmaceutical company focused on controlling immune system responses, today announced positive results from a phase II clinical study of its anti-allergy technology, ToleroMune®, in the field of cat allergy. The trial...

View details

Circassia Announces the Appointment of Guy Layton as Director of Alloimmune Projects

Circassia Ltd, a specialty biopharmaceutical company focused on controlling immune system responses, today announced the appointment of experienced R&D scientist Dr Guy Layton as Director of Alloimmune Projects. “Following the acquisition of the novel ToleroTrans...

View details

Circassia Announces the Appointment of Pascal Hickey as Vice President Early Development

Circassia Ltd, a specialty biopharmaceutical company focused on controlling immune system responses, today announced the appointment of Dr Pascal Hickey as Vice President, Early Development. “We are very pleased with Pascal’s addition to the management...

View details

Circassia Initiates Phase II Clinical Study With Novel Anti-Allergy Technology

OXFORD, UK – 27 February 2008 – Circassia Ltd, a specialty biopharmaceutical company focused on controlling immune system responses, announced today that it has initiated a phase II clinical study with its anti-allergy technology, ToleroMune....

View details

Circassia Raises £11 million ($21.8 million) In Oversubscribed Second Round Funding

OXFORD, UK – 29 January 2008 – Circassia Ltd, a specialty biopharmaceutical company focused on controlling immune system responses, announced today that it has successfully raised £11 million ($21.8 million) in an oversubscribed second round...

View details

Circassia Completes In-Licensing of Anti-Allergy Intellectual Property Portfolio

OXFORD, UK – 29 November 2007 – Circassia Ltd, a specialty biopharmaceutical company focused on controlling immune system responses, today announced the in-licensing of anti-allergy intellectual property from Monash University in Australia and the Vienna-based...

View details